Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

202016 citationsJournal Articlegold Open Access

Authors

Jane E. Rogers · The University of Texas MD Anderson Cancer Center

Jonathan D. Mizrahi · The University of Texas MD Anderson Cancer Center

Lianchun Xiao · The University of Texas MD Anderson Cancer Center

Chirayu Mohindroo · The University of Texas MD Anderson Cancer Center

Rachna T. Shroff · The University of Texas MD Anderson Cancer Center

Robert A. Wolff · The University of Texas MD Anderson Cancer Center

Abstract

Our analysis revealed safety with every two-week low dose GEM-NabP while maintaining efficacy. Patient schedule convenience should factor into metastatic incurable malignancies. We suggest the use of every two-week GEM-NabP particularly in patients desiring a modified schedule.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Medicine

Volume 9, Issue 15, pp. 5406-5415

DOI: 10.1002/cam4.3229

Field-Weighted Citation Impact: 0.67